Financing ·
Yarrow Bioscience, Inc. entered into an underwriting agreement on September 10, 2026, to sell 5,769,231 shares of…
VYNEYarrow Bioscience, Inc.
Yarrow Bioscience, Inc. entered into an underwriting agreement on September 10, 2026, to sell 5,769,231 shares of common stock at $26.00 per share. The underwriters exercised their option for an additional 865,384 shares on September 11, 2026. Net proceeds are expected to be approximately $161.8 million after deducting discounts and offering expenses. The offering closed on September 14, 2026, with directors and executives subject to a 60-day lock-up period. Yarrow Bioscience operates in the biotechnology industry, focusing on drug discovery and development.